Sarepta Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Sarepta (SRPT) Conditional-Approval Thesis Unchanged, Roth Capital Says
November 6, 2015 8:17 AM ESTRoth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT), saying their conditional-approval thesis remains unchanged.
Chattopadhyay commented, "A new therapy is not considered available therapy if granted accelerated approval based on a surrogate or... More
Needham & Company Maintain High Conviction for Sarepta (SRPT) Eteplirsen Approval
November 6, 2015 6:53 AM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they maintain high conviction in Eteplirsen approval.
Messer commented, "SRPT shares have pulled back from recent highs due to concerns that etelpirsen's later than expected... More
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 7c
November 5, 2015 7:04 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.11), $0.07 better than the analyst estimate of ($1.18).
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
... More